SCHOLAR ROCK HOLDING CORP
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Find out what a historical investment in SCHOLAR ROCK HOLDING CORP would be worth today using our SRRK stock calculator.
$5.73B
-
0.00%
1.2M
$51.63
$49.39
$51.00
$50.50
$22.71
Ready to start your investing journey with Stake?
Open an accountSRRK FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in SRRK
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in SRRK
on Stake
Buy SRRK from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of SRRK from only US$10 with fractional shares
